The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma

Web

Nov. 12, 2019

SCIENTIFIC

Preclinical models and clinical data suggest differential drug sensitivities for different EGFR exon 19 indels, with the rarer EGFR L747_A750delinsP mutation showing reduced sensitivity to erlotinib & osimertinib but high sensitivity to afatinib.

https://clincancerres.aacrjournals.org/content/25/21/6382